DOCSLIB.ORG

TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies Author Manuscript Published OnlineFirst on April 28, 2016; DOI: 10.1158/1078-0432.CCR-15-2783 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. TAS-102 for Treatment of Advanced Colorectal Cancers that Are No Longer Responding to Other Therapies Daphne L. van der Velden1, Frans L. Opdam2, and Emile E. Voest1 1 The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Department of Molecular Oncology, Amsterdam, the Netherlands 2 The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Department of Clinical Pharmacology, Amsterdam, the Netherlands Corresponding Author: Frans L. Opdam, Division of Medical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Postbus 90203, 1006 BE Amsterdam, the Netherlands. E-mail: [email protected] Running Title: TAS-102 for Treatment of Advanced Colorectal Cancer Disclosure of Potential Conflicts of Interest No potential conflicts of interest were disclosed. Abstract TAS-102 is a novel oral formulation of trifluridine (TFT) and tipiracil hydrochloride (TPI), a thymidine phosphorylase inhibitor. TFT was originally synthesized in the 1960s and is a nucleoside analog that impedes DNA synthesis by inhibition of thymidylate synthase. TFT’s main mechanism of action however seems to be its incorporation into DNA, which distinguishes TFT from current well-known antimetabolites like 5-fluorouracil (5-FU). The rapid degradation of TFT brought initial clinical development to a halt, but TFT re-entered clinical trials when addition of a TPI was found to improve the bio-availability of TFT. The combined TFT-TPI formulation was tested in patients with treatment- refractory metastatic colorectal cancer in the randomized phase III RECOURSE study. Compared to placebo, TAS-102 was associated with an overall and progression free survival benefit and a 32% reduction in risk of death (median OS 7.1 (95% CI 6.5-7.8) vs. 5.3 months (95% CI 4.6-6.0), median PFS 2.0 (95% CI 1.9-2.1) vs 1.7 months (95% CI 1.7-1.8), HR for death 0.68 (95% CI 0.58-0.81, p<0.001)). Based on the results of this pivotal trial and supported by results from an earlier phase II study, TAS-102 recently gained FDA approval. This article reviews the development of TAS-102 and its therapeutic value for the proposed indication. Introduction Worldwide, colorectal cancer (CRC) is the third most frequently diagnosed cancer in men and the second in women, with over 1.4 million new cases diagnosed in 2012. Approximately 25% of patients have metastatic disease at the time of presentation and almost 50% will develop metastases eventually (1, 2). A minority of patients with metastatic disease can be treated by surgery, which is the preferred treatment if feasible. In most cases of metastatic CRC (mCRC) though, resection is not feasible and chemotherapy is the mainstay of palliative treatment for the majority of patients. 1 Downloaded from clincancerres.aacrjournals.org on October 2, 2021. © 2016 American Association for Cancer Research. Author Manuscript Published OnlineFirst on April 28, 2016; DOI: 10.1158/1078-0432.CCR-15-2783 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Until the beginning of this century, 5-fluorouracil (5-FU) was the only anticancer drug available for systemic treatment of mCRC. Fortunately the number of available therapies has expanded, and median survival of mCRC patients has improved markedly since oxaliplatin, irinotecan, bevacizumab (an VEGF- inhibitor), cetuximab and panitumumab (EGFR-inhibitors) have been introduced. For mCRC patients who have progressed on these therapies, the National Comprehensive Cancer Network (NCCN) guideline currently lists three options: best supportive care, participation in a clinical trial, or treatment with regorafenib. Regorafenib, a multi-kinase inhibitor, is the only systemic treatment option that has demonstrated statistically significant survival benefit in a randomized, placebo-controlled trial. The overall survival benefit of regorafenib was 1.4 months and 50% of patients developed progressive disease within two treatment cycles, often accompanied by severe toxicity (3). Altogether, this emphasizes the need for additional treatment options for patients who have exhausted all initial therapies. TAS-102 (Lonsurf ®) is a novel oral formulation of the combination of trifluorothymidine (trifluridine or TFT) and tipiracil hydrochloride (TPI), a thymidine phosphorylase inhibitor (Figure 1). TFT was originally synthesized in 1964 (4). Despite promising anti-tumor activity in breast and colon cancer (5), clinical development was discontinued due to unacceptable toxicity and a poor pharmacokinetic profile. The rapid degradation of TFT by thymidine phosphorylase (TP) led to a mean plasma half-life of TFT of less than 15 minutes (6). Only after a potent TP inhibitor (TPI) became available, clinically meaningful plasma TFT concentrations could be reached (7, 8). Optimal TFT concentrations were obtained with TFT and TPI in a 1:0.5 molar ratio (9). Interestingly, the formulation (named TAS-102) showed anti-tumor activity against both 5-FU sensitive and resistant models in pre-clinical studies (10, 11). Its activity in 5-FU resistant tumors was confirmed in clinical studies, where TAS-102 showed anti-tumor activity in mCRC patients who had exhausted all above-mentioned therapies. TAS-102 might hereby represent an important new therapeutic option for treatment-refractory mCRC patients. Clinical development Multiple phase I trials of TAS-102 monotherapy were conducted to determine the maximum tolerated dose (MTD) and optimal dosing schedule (Table 1). The first phase I study enrolled 14 patients with therapy-refractory mCRC. Based on a preclinical monkey model, treatment was administered once daily during 14 days in a 21 day schedule. 50 mg/m2/day was declared the MTD, with neutropenia being the DLT. No objective tumor responses were observed, but stable disease (SD) was observed in 29% of patients (12). Even though no DLTs occurred at 50 mg/m2/day, myelotoxicity appeared more pronounced in later treatment cycles. This seemed to be explained by progressive drug accumulation as observed at the end of every treatment cycle. Two additional phase I studies were therefore initiated to define a dosing interval that would minimize hematologic toxicity. TAS-102 was administered once daily for five days per week in both studies, either on a 2-weeks-on, 2-weeks-off schedule (n = 24), or on a 1-week-on, 2- weeks-off schedule (n = 39). The recommended phase II dose for these schedules was 100 and 160 mg/m2/day, respectively. Since the 2-week rest between doses did not decrease blood concentration of FTD, and because of the higher administered dose, the 2-weeks-on, 2-weeks-off schedule was 2 Downloaded from clincancerres.aacrjournals.org on October 2, 2021. © 2016 American Association for Cancer Research. Author Manuscript Published OnlineFirst on April 28, 2016; DOI: 10.1158/1078-0432.CCR-15-2783 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. recommended. Consistent with the data from the study by Hong et al, neutropenia was the DLT for both dosing schedules. No objective responses were seen, but SD was observed in almost 30% of patients (13). Because of the limited anti-tumor activity of TAS-102 in these studies, and because earlier studies suggested improved antitumor activity of FTD when administered in multiple daily-doses (5, 14, 15), another phase I study was initiated in which TAS-102 treatment was divided over three daily doses (16). In this study 60 mg/m2/day was declared the recommended phase II dose. Although no objective responses according to RECIST criteria were seen, five patients did demonstrate radiographic reductions in tumor burden and 60% of patients had SD. Based on these results an additional phase I study was initiated in Japan to establish the MTD and optimal phase II dose in Japanese patients (17). Patients were treated with two daily doses for five days per week on the 2-weeks-on, 2-weeks-off schedule. Although the MTD was not reached, 35 mg/m2 twice daily already caused grade 3 neutropenia in three out of six patients and was therefore declared the recommended dose for subsequent studies. No objective tumor responses were observed, but 52% of patients showed SD with a mean duration of 2.5 months. This study was followed by a double-blind phase II trial of 169 Japanese patients with unresectable chemo-refractory mCRC (18). Patients were randomized between placebo or TAS-102 35 mg/m2 twice daily for five days per week on a 2-weeks-on, 2-weeks-off schedule, based on the study by Doi et al (17). One patient in the TAS-102 group (1%) achieved a partial response, whilst no objective responses were observed in the placebo group. Median overall survival (OS) was 9.0 months (95% CI 7.3-11.3) in the TAS-102 treated patients (n = 112) and 6.6 months (95% CI 4.9-8.0) in the placebo group (n = 57; hazard ratio for death 0.56, p = 0.001) (18). One more phase I study was initiated to confirm the safety of the 35 mg/m2 twice daily in Western mCRC patients (19). Based on treatment of 27 patients with chemo-refractory mCRC, 35 mg/m2 twice daily was indeed declared the recommended dose for Western mCRC patients. SD was reached in 65% of patients with a median PFS and OS of 4.1 and 8.9 months, similar to the results of the Japanese phase II trial. A double-blind, randomized, placebo-controlled phase III study (RECOURSE trial) was then conducted to assess the efficacy and safety of TAS-102 in a global population of mCRC patients who were refractory or intolerant to standard of care therapy (20).
Load more

Recommended publications
  • Lonsurf (Trifluridine/Tipiracil) Were Bone Marrow Suppression and Gastrointestinal Toxicity
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrLONSURF® trifluridine and tipiracil tablet 15 mg trifluridine/ 6.14 mg tipiracil (as tipiracil hydrochloride) 20 mg trifluridine / 8.19 mg tipiracil (as tipiracil hydrochloride) Antineoplastic Agent Thymidine phosphorylase inhibitor/nucleoside metabolic inhibitor Taiho Pharma Canada, Inc. Date of Initial Approval: 2010 Winston Park Drive, Suite 503 January 23, 2018 Oakville, Ontario L6H 5R7 Canada Submission Control No: 205852 Page 1 of 35 RECENT MAJOR LABEL CHANGES Not Applicable TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ......................................................................................2 TABLE OF CONTENTS ..............................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION ............................................................4 1 INDICATIONS....................................................................................................................4 1.1 Pediatrics ....................................................................................................................4 1.2 Geriatrics ....................................................................................................................4 2 CONTRAINDICATIONS ..................................................................................................4 3 DOSAGE AND ADMINISTRATION ...............................................................................4 3.1 Dosing Considerations
    [Show full text]
  • LONSURF® (Trifluridine and Tipiracil) Tablets Are a Prescription Medicine Used to Treat People with Colon Or Rectal Cancer That
    LONSURF® (trifl uridine and tipiracil) tablets are a prescription medicine used to treat people with colon or rectal cancer that has spread to other parts of the body and who have been previously treated with or cannot receive certain chemotherapy medicines. It is not known if LONSURF is safe and effective in children. In a clinical trial, half of the patients treated with LONSURF were still alive at 7.1 months and half of the patients who received placebo were still alive at 5.3 months. Worsening of the disease or death occurred in 88% of patients treated with LONSURF and 94% of patients who received placebo. Selected Important Safety Information Low blood counts. LONSURF can decrease the number of your blood cells. This can sometimes be severe and life-threatening. Please see Important Safety Information on pages 18 and 19 and full Prescribing Information in pocket. Table of contents 4 About this booklet Support, tools, and resources 5 About colon or rectal cancer 34 Taiho Oncology Patient Support 35 LONSURF Starter Kit About LONSURF® (trifl uridine and tipiracil) tablets 36 Online resources 8 What is it? 37 Advocacy groups 9 Who is it for? 10 How it works Living with and managing colon or rectal cancer 11 What to expect 40 Coping with advanced colon or rectal cancer 14 How to take it 42 Tips for your appointments 44 Tips for your caregivers Safety 18 Important Safety Information Appendix 20 Managing side effects 48 Glossary 31 Potential treatment changes 54 Journal 60 Important contact information Please see Important Safety Information on pages 18 and 19 and full Prescribing Information in pocket.
    [Show full text]
  • These Highlights Do Not Include All the Information Needed to Use LONSURF Safely and Effectively
    LONSURF- trifluridine and tipiracil tablet, film coated Taiho Pharmaceutical Co., Ltd. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LONSURF safely and effectively. See full prescribing information for LONSURF. LONSURF (trifluridine and tipiracil) tablets, for oral use Initial U.S. Approval: 2015 RECENT MAJOR CHANGES Indications and Usage (1.2) 2/2019 Recommended Dosage (2.1) 2/2019 Warnings and Precaution (5.1) 2/2019 INDICATIONS AND USAGE LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with: metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. (1.1) metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu- targeted therapy. (1.2) DOSAGE AND ADMINISTRATION Recommended Dosage: 35 mg/m2/dose orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle. (2.1) DOSAGE FORMS AND STRENGTHS Tablets: 15 mg trifluridine/6.14 mg tipiracil (3) 20 mg trifluridine/8.19 mg tipiracil (3) CONTRAINDICATIONS None. (4) WARNINGS AND PRECAUTIONS Severe Myelosuppression: Obtain complete blood counts prior to and on Day 15 of each cycle. Withhold and resume at next lower LONSURF dosage as recommended. (2.1, 5.1) Embryo-Fetal Toxicity: Can cause fetal harm.
    [Show full text]
  • Patient Assistance Brochure | LONSURF® (Trifluridine and Tipiracil)
    Important Safety Information LONSURF® (trifl uridine and tipiracil) may cause serious side effects, including: • Low blood counts. Low blood counts are common with LONSURF and can sometimes be severe and life-threatening. LONSURF can cause a decrease in your white blood cells, red blood cells, and platelets. Low white blood cells can make you more likely to get serious infections that could lead to death. Your healthcare provider should do blood tests before you receive LONSURF, at day 15 during treatment with LONSURF, and as needed to check your blood cell counts. Your healthcare provider may lower your dose of LONSURF or stop LONSURF if you have low white blood cell or platelet counts Tell your healthcare provider right away if you get any of the following signs and symptoms of infection during treatment with LONSURF: fever, chills, or body aches. Before taking LONSURF, tell your healthcare provider about all of your medical conditions, including if you: • Have kidney problems • Are pregnant or plan to become pregnant. LONSURF can harm your unborn baby – Females who can become pregnant should use effective birth control during treatment with LONSURF. Tell your healthcare provider immediately if you become pregnant – Males , while on treatment and for 3 months after your last dose of LONSURF, you should use a condom during sex with female partners who are able to become pregnant. Tell your healthcare provider right away if your partner becomes pregnant while you are taking LONSURF • Are breast-feeding or plan to breast-feed. It is not known if LONSURF passes into your breast milk.
    [Show full text]
  • Lonsurf, INN-Trifluridine / Tipiracil
    25 February 2016 EMA/CHMP/287846/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Lonsurf International non-proprietary name: trifluridine / tipiracil Procedure No. EMEA/H/C/003897/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact An agency of the European Union Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ..................................................................................... 7 1.2. Steps taken for the assessment of the product ........................................................ 8 2. Scientific discussion ................................................................................ 9 2.1. Introduction ........................................................................................................ 9 2.2. Quality aspects .................................................................................................. 12 2.2.1. Introduction.................................................................................................... 12 2.2.2. Active substance ............................................................................................ 13 Trifluridine ..............................................................................................................
    [Show full text]
  • Study Protocol and Statistical Analysis Plan
    MC1642 3 Table of Contents Phase II Trial of FTD/TPI (TAS-102) in Biliary Tract Cancers ................................................................... 1 Protocol Resources ........................................................................................................................................ 2 Table of Contents .......................................................................................................................................... 3 Schema .......................................................................................................................................................... 4 1.0 Background ................................................................................................................................... 5 2.0 Goals ............................................................................................................................................. 8 3.0 Patient Eligibility .......................................................................................................................... 9 4.0 Study Schedules .......................................................................................................................... 11 5.0 Stratification Factors OR Grouping Factor: ................................................................................ 12 6.0 Registration Procedures .............................................................................................................. 12 7.0 Protocol Treatment .....................................................................................................................
    [Show full text]
  • 207981Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 207981Orig1s000 PHARMACOLOGY REVIEW(S) MEMORANDUM Lonsurf (trifluridine and tipiracil) Date: September 18, 2015 To: File for NDA 207981 From: John K. Leighton, PhD, DABT Director, Division of Hematology Oncology Toxicology Office of Hematology and Oncology Products I have examined pharmacology/toxicology supporting and labeling reviews for Lonsurf conducted by Drs. Khasar and Fox, and secondary memorandum and labeling provided by Dr. Helms. Following finalization of the primary and secondary reviews, additional discussion occurred about the proper description of the established pharmacological class (EPC) for this combination product. As the anticancer activity of the drug is through the action of the trifluridine portion of the drug, the original recommendation was to use the EPC for this portion of the drug to describe the EPC for LONSURF. Upon further review and discussion, and consistent with practices with other combination products in which one component of the product is present primarily to affect the pharmacokinetics of the other component, the Division revised the recommendation for the EPC for LONSURF to be “LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for…” I concur with Dr. Helms’ conclusion that Lonsurf may be approved for the proposed indication and that no additional nonclinical studies are needed. Reference ID: 3821960 --------------------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. --------------------------------------------------------------------------------------------------------- /s/ ---------------------------------------------------- JOHN K LEIGHTON 09/18/2015 Reference ID: 3821960 MEMORANDUM Date: August 25 , 2015 From: Whitney S.
    [Show full text]
  • Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors
    Published OnlineFirst January 10, 2020; DOI: 10.1158/1078-0432.CCR-19-2743 CLINICAL CANCER RESEARCH | CLINICAL TRIALS: TARGETED THERAPY Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors A C Anna M. Varghese1, Dana B. Cardin2, Jonathan Hersch1, Al B. Benson3, Howard S. Hochster4, Lukas Makris5, Kensuke Hamada6, Jordan D. Berlin2, and Leonard B. Saltz1 ABSTRACT ◥ Purpose: This two-part phase Ib trial determined the maximum toxicities (fatigue and neutropenia) were observed in the dose- tolerated dose (MTD) of the combination of trifluridine/tipiracil escalation phase, and MTD was defined as FTD/TPI 25 mg/m2 (FTD/TPI) and irinotecan in patients with advanced gastrointes- twice daily plus irinotecan 180 mg/m2.Intheexpansionphase, tinal tumors, and evaluated the safety, pharmacokinetics, and 83% (20/24) experienced any-cause grade 3 adverse events antitumor activity of the FTD/TPI, irinotecan, and bevacizumab (AEs) with the triplet combination, most frequently neutropenia triplet combination in previously treated metastatic colorectal (42%), leukopenia (25%), and diarrhea (12%). AEs of any-cause cancer (mCRC). led to dosing interruptions, modifications, and discontinuations Patients and Methods: Dose escalation (3þ3 design) in advanced in 29%, 17%, and 4% of patients, respectively. No treatment- gastrointestinal tumors was followed by expansion in mCRC. related deaths occurred. Three patients (12%) experienced partial During dose escalation, patients received FTD/TPI (20–35 mg/m2 responses and 16 (67%) patients had stable disease lasting twice daily; days 1–5 of a 14-day cycle) and irinotecan (120– >4 months. The median progression-free survival was 7.9 months 180 mg/m2; day 1).
    [Show full text]
  • Auspar Attachment 1: Product Information: Trifluridine/Tipiracil
    Attachment 1: Product information for AusPAR Lonsurf and Orcantas Servier Laboratories Australia Pty Ltd PM-2016-00929-1-4 Final 12 June 2018. This Product Information was approved at the time this AusPAR was published. LONSURF (trifluridine/tipiracil) – Product Information 1 (20) Product Information NAME OF THE MEDICINE LONSURF 15/6.14 Trifluridine 15 mg/ tipiracil hydrochloride 7.065 mg (equivalent to tipiracil 6.14 mg) LONSURF 20/8.19 Trifluridine 20 mg/ tipiracil hydrochloride 9.420 mg (equivalent to tipiracil 8.19 mg) The active components of LONSURF are trifluridine and tipiracil hydrochloride. Trifluridine Trifluridine has the chemical name 2′-deoxy-5-(trifluoromethyl)uridine Chemical structure: Molecular formula: C10H11F3N2O5 (Relative Molecular Mass: 296.20) CAS Registry Number: 70-00-8 Tipiracil hydrochloride Tipiracil hydrochloride has the chemical name 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine- 2,4-(1H,3H)-dione monohydrochloride. Chemical structure: Molecular formula: C9H11ClN4O2•HCl (Relative Molecular Mass: 279.12) CAS Registry Number: 183204-72-0 DESCRIPTION Trifluridine is a white crystalline powder, soluble in water, ethanol, 0.01 mol/L hydrochloric acid, 0.01 mol/L sodium hydroxide solution; freely soluble in methanol, acetone; sparingly soluble in 2- propanol, acetonitrile; slightly soluble in diethyl ether; and very slightly soluble in isopropyl ether. Tipiracil hydrochloride is a white crystalline powder, soluble in water, 0.01 mol/L hydrochloric acid, and 0.01 mol/L sodium hydroxide; slightly soluble in methanol; very slightly soluble in ethanol; and practically insoluble in acetonitrile, 2-propanol, acetone, diisopropyl ether, and diethyl ether. Version 1 Attachment 1: Product information for AusPAR Lonsurf and Orcantas Servier Laboratories Australia Pty Ltd PM-2016-00929-1-4 Final 12 June 2018.
    [Show full text]
  • Extract from the Clinical Evaluation Report for Trifluridine/Tipiracil
    AusPAR Attachment 2 Extract from the Clinical Evaluation Report for trifluridine / tipiracil Proprietary Product Name: Lonsurf and Orcantas Sponsor: Servier Laboratories Australia Pty Ltd First round report: July 2016 Second round report: January 2017 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health, and is responsible for regulating medicines and medical devices. • The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About the Extract from the Clinical Evaluation Report • This document provides a more detailed evaluation of the clinical findings, extracted from the Clinical Evaluation Report (CER) prepared by the TGA. This extract does not include sections from the CER regarding product documentation or post market activities. • The words (Information redacted), where they appear in this document, indicate that confidential information has been deleted. • For the most recent Product Information (PI), please refer to the TGA website <https://www.tga.gov.au/product-information-pi>.
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrLONSURF® trifluridine and tipiracil tablet 15 mg trifluridine/ 6.14 mg tipiracil (as tipiracil hydrochloride) 20 mg trifluridine / 8.19 mg tipiracil (as tipiracil hydrochloride) Antineoplastic Agent Thymidine phosphorylase inhibitor/nucleoside metabolic inhibitor Taiho Pharma Canada, Inc. Date of Initial Approval: 2010 Winston Park Drive, Suite 503 JAN 23, 2018 Oakville, Ontario L6H 5R7 Date of Revision: Canada OCT 29, 2020 Submission Control No: 235999 Page 1 of 37 RECENT MAJOR LABEL CHANGES INDICATIONS (1) 11-2019 WARNINGS AND PRECAUTIONS (6), Geriatrics (6.1.4) 11-2019 DOSAGE AND ADMINISTRATION (3.3) 10-2020 WARNINGS AND PRECAUTIONS (6), Renal 10-2020 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ........................................................................... 2 TABLE OF CONTENTS ................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................... 4 1 INDICATIONS ..................................................................................................... 4 1.1 Pediatrics .................................................................................................... 4 1.2 Geriatrics .................................................................................................... 4 2 CONTRAINDICATIONS ...................................................................................... 4 3 DOSAGE AND ADMINISTRATION ...................................................................
    [Show full text]
  • Trifluridine-Tipiracil
    Trifluridine-tipiracil DRUG NAME: Trifluridine-tipiracil SYNONYM(S): TAS-1021 COMMON TRADE NAME(S): LONSURF® CLASSIFICATION: antimetabolite Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Trifluridine-tipiracil is an orally administered antimetabolite comprised of an antineoplastic thymidine-based nucleoside analogue (trifluridine), and a thymidine phosphorylase inhibitor (tipiracil). Once inside the cell, trifluridine is phosphorylated by thymidine kinase and incorporated into DNA, thereby interfering with DNA synthesis and preventing cell proliferation. Tipiracil enhances the oral availability of trifluridine by inhibiting its rapid degradation and subsequent first-pass metabolism by thymidine phosphorylase.1-4 PHARMACOKINETICS: Oral Absorption trifluridine: bioavailability = 57%, tmax = 2 h; tipiracil: bioavailability = 27%, tmax = 3 h; food effect: high-fat, high-calorie food intake reduces trifluridine Cmax and tipiracil Cmax and AUC by 40% Distribution cross blood brain barrier? no information found volume of distribution5 trifluridine: 21 L; tipiracil: 333 L plasma protein binding trifluridine: > 96% (mainly serum albumin); tipiracil: < 8% Metabolism independent of cytochrome P450 enzymes active metabolite(s) no information found inactive metabolite(s) trifluridine: 5-trifluoromethyl uracil (FTY) and others; tipiracil: 6-hydroxymethyluracil Excretion negative correlation between serum albumin levels and trifluridine clearance urine trifluridine: 55%; tipiracil: 27% feces trifluridine: <3%; tipiracil: 50% terminal half life trifluridine: 2 h; tipiracil: 2.4 h clearance trifluridine: 3 L/h; tipiracil: 90 L/h Adapted from standard reference1,3,4 unless specified otherwise. USES: Primary uses: Other uses: *Colorectal cancer *Gastric cancer *Health Canada approved indication BC Cancer Drug Manual©. All rights reserved. Page 1 of 6 Trifluridine-tipiracil This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy.
    [Show full text]